Welcome to the e-CCO Library!

P670: Identification of two additional susceptibility loci for Crohn's disease in Koreans
Year: 2021
Source: ECCO'21 Virtual
Authors: Lee, H.S.(1);Jung, S.(1);Ye, B.D.(2);Baek, J.(1);Park, D.(1);Park, S.H.(2);Yang, S.K.(2);Song, K.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P670: Therapeutic efficacy and economic impact of half sulfasalazine therapy for refractory ulcerative colitis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Kunisaki*1, M. Tatsuno1, J. Kouyama1, C. Kawamoto1, H. Nishioka1, A. Mizoguchi1, Y. Nakamori1, T. Mitsui1, K. Chida1, Y. Hashimoto1, Y. Tamura1, A. Ikeda1, T. Ogashiwa1, R. Suzuki2, S. Maeda3, H. Kimura1

Created: Friday, 22 February 2019, 9:41 AM
P670: “What Matters To You?” – How do patient views compare with a patient experience framework and UK national standards of care?
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Sheldon, E.(1)*;Roman, S.(2);Randall, K.(2);Rachel, H.(3);Winsor, G.(4);Wakeman, R.(5);Lobo, A.(2);
Created: Friday, 14 July 2023, 11:12 AM
P671 Natural history and clinical outcomes of patients with ulcerative colitis who are intolerant to 5-aminosalicylic acid agents: A multi-centre cohort study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Madarame1, H. Kinoshita1, T. Yamaguchi1, Y. Izumi1, Y. Nishikawa1, S. Shonai1, M. Tatsuno1, Y. Ishii1, K. Yaguchi1, Y. Nakamori1, A. Ikeda1, K. Araki1, A. Hirayama1, T. Ogashiwa1, A. Fuji1, R. Suzuki2, H. Kimura1, R. Kunisaki1

Created: Thursday, 30 January 2020, 10:12 AM
P671: Calprotectin does not add accuracy to PRO2 for prediction of continuous clinical response in moderate-to-severe ulcerative colitis patients treated with golimumab
Year: 2018
Source: ECCO '18 Vienna
Authors:

F. Cornillie1*, L. Peyrin-Biroulet2, J. Long3, G. Philip3

Created: Thursday, 21 February 2019, 9:14 AM
P671: Early suppression of the serological macrophage activity biomarker VICM, and not suppression of CRP, predicts the response to infliximab in Crohn's disease patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Mortensen J.H.*1, van Haaften W.T.2,3, Olesen M.L.1,4, Karsdal M.1, Olinga P.2, Dijkstra G.3, Bay-Jensen A.-C.1

Created: Wednesday, 20 February 2019, 10:36 AM
P671: Effect of genetic polymorphisms in the folate pathway on the efficacy and safety of methotrexate in Crohn’s disease.
Year: 2021
Source: ECCO'21 Virtual
Authors: Salazar, J.(1);Gordillo Abalos, J.(2);Fernández, A.(3);Esteve, M.(4);Pérez Gisbert, J.(5);Busquets, D.(6);Lucendo, A.(7);Márquez, L.(8);Guardiola, J.(9);Martin, M.D.(10);Iglesias, E.(11);Monfort, D.(12);Villoria, A.(13);Cañete, F.(14);Bell, O.(1);Ricart, E.(3);Zabana, Y.(4);Domènech, E.(14);Garcia-Planella, E.(2);
Created: Wednesday, 2 June 2021, 4:12 PM
P671: Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands: a retrospective observational study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

J. R. White1,2,3, S. Din3, R. Ingram4, S. Foley4, M. A. Alam5, R. Robinson5, R. Francis2, E. Tucker2, M. Jalal6, D. Elphick6, E. Atallah1,7, A. Norman7, M. Amin8, A. Sajjad8, N. Heggs9, S. Meadowcroft9, G. Moran*1,2

Created: Friday, 22 February 2019, 9:41 AM
P671: Occurrence and clinical impact of eosinophilic esophagitis in a large cohort of children with Inflammatory Bowel Disease.
Year: 2022
Source: ECCO'22
Authors: Aloi, M.(1);Rossetti, D.(1);Bucherini, S.(1);Felici, E.(2);Romano, C.(3);Martinelli, M.(4);Di Pasquale, V.(5);Lionetti, P.(6);Oliva, S.(7);
Created: Friday, 11 February 2022, 3:56 PM
P671: Ustekinumab in paediatric patients with moderately to severely active Crohn's disease: Results from the UniStar study long-term extension
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Turner, D.(1)*;Rosh, J.R.(2);Cohen, S.A.(3);Griffiths, A.(4);Hyams, J.S.(5);Kierkuś, J.(6);Adedokun, O.J.(7);Strauss, R.(8);Kim, L.(9); Volger, S.(10);
Created: Friday, 14 July 2023, 11:12 AM
P672 The escalation of therapy or intervention (ETI) calculator for ulcerative colitis: does it have the potential to help outpatient capacity meet demand?
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A.J. Walsh, L. Matini, R. Kantschuster, M. Lepetyukh, D. Simadibrata, G. Collins, J. Wilson, M. Hussain, A. Tarafdar, O. Brain, R. Palmer, T. Ambrose, J. Satsangi, S.P.L. Travis

Created: Thursday, 30 January 2020, 10:12 AM
P672: A tertiary multicenter cohort of patients with chronic intestinal pseudo-obstruction and Crohn’s disease: a rare association with a high prevalence of monogenic disorders.
Year: 2021
Source: ECCO'21 Virtual
Authors: De Castelbajac, F.(1);Charbit-Henrion, F.(2);Goulet, O.(3);Cerf-Bensussan, N.(4);Treton, X.(1);Stefanescu, C.(1);Cazals-Hatem, D.(5);Billiauws, L.(1);Bouhnik, Y.(1);Joly, F.(1);Uzzan, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P672: Biologic therapy for Inflammatory Bowel Disease in Poland in 2020: nationwide data.
Year: 2022
Source: ECCO'22
Authors: Kucha, P.(1);Zagórowicz, E.(1,2);Walkiewicz, D.(3);Perwieniec, J.(3);Maluchnik, M.(3,4);Wieszczy, P.(2);Reguła, J.(1,2);
Created: Friday, 11 February 2022, 3:56 PM
P672: Drug therapy and monitoring for inflammatory bowel diseases: preliminary data from a multi-centre investigation in Asia
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

C. Cai1, J. Shen1, J. Tong1, J. Lu1, Q. Zheng1, K. Wu2, J. Qian3, Z. Ran*1

Created: Friday, 22 February 2019, 9:41 AM
P672: Surgical and anti-TNFs combined therapy prevents Crohn's perianal fistula recurrence: a systematic review and meta-analysis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Xu P.-p.*1, Qiu Y.2, Jia Y.-l.1, Xu L.1, He C.-y.1, Han Z.1

Created: Wednesday, 20 February 2019, 10:36 AM
P672: Switching out of class or to another anti-TNF agent is the most effective strategy in IBD patients with immunogenicity against anti-TNF antibodies
Year: 2023
Source: ECCO’23 Copenhagen
Authors: AnjieMD, S.(1)*;Hanžel, J.(2);Gecse, K.B.(1);D'Haens, G.R.(1);Brandse, J.F.(3);
Created: Friday, 14 July 2023, 11:12 AM
P673 Strategy of selecting anti-TNF agent in patients with Crohn’s disease: A multi-centre retrospective cohort study by the Osaka gut forum
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Amano, S. Shinzaki, T. Tashiro, Y. Otake, M. Tani, T. Yoshihara, S. Iwatani, Y. Tsujii, T. Inoue, Y. Hayashi, H. Iijima, T. Takehara, Osaka Gut Forum

Created: Thursday, 30 January 2020, 10:12 AM
P673: Achievement of tight control based on serum C-reactive protein and albumin correlated with better outcomes in Japanese Crohn’s disease patients treated with biologics
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

H. Shiga*1, I. Abe1, M. Onodera1, R. Moroi1, M. Kuroha1, Y. Kanazawa1, Y. Kakuta1, Y. Kinouchi1,2, A. Masamune1

Created: Friday, 22 February 2019, 9:41 AM
P673: Intra-abdominal collections in Crohn's disease: outcomes following anti-TNF therapy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Subramaniam K.*1,2, Tweedale M.1, Pavli P.1,2

Created: Wednesday, 20 February 2019, 10:36 AM